APRE: WEE1 inhibitor demonstrates promising efficacy and safety, with key data updates expected in Q4
The session highlighted progress in synthetic lethality oncology, with a WEE1 inhibitor showing promising efficacy and safety in biomarker-defined cancers. Dose escalation established 150 mg as the minimum efficacious dose, and further data updates are expected in Q4.Based on Aprea Therapeutics, In…